BUSINESS MODEL

To develop patent-protected drugs, which can extend life and reduce healthcare costs, for sales tothe international pharmaceutical industry and further clinical trials.

Out-licensing of drug candidates is expected to take place against partial payments on signing and milestones in product development (typically when initiating clinical phase I, II, III and when registering) and royalty income.